CD4 and neoplasm: The data on anti-RANKL/anti-PD1/anti-CTLA4 combination therapy showed promising results in a higher proportion of tumor-infiltrating CD4+ and CD8+ T cells that can produce both IFNγ and TNFα after anti-RANKL treatment.